JAN ANDERSSON

Dr. JAN ANDERSSON

Alberta Health Services
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BNBryce Nelson
Bryce Nelson
JAJAN ANDERSSON
JAN ANDERSSON
Frank WuestFrank Wuest
Frank Wuest
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.

17 November 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BNBryce Nelson
Bryce Nelson
JWJohn Wilson
John Wilson
JAJAN ANDERSSON
JAN ANDERSSON
Frank WuestFrank Wuest
Frank Wuest
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: 133La, 132La, 134Ce/134La, and 226Ac for 225Ac TAT; 203Pb for 212Pb TAT; 131Ba for 223Ra and 224Ra TAT; 123I, 124I, 131I and 209At for 211At TAT; 134Ce/134La for 227Th TAT; and 155Tb and 152Tb for 149Tb TAT.

2 January 2024 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
AKAruna Korde
Aruna Korde
MPMarianne Patt
Marianne Patt
SSSvetlana V. Selivanova
Svetlana V. Selivanova
Andrew ScottAndrew Scott
Andrew Scott
RHRolf Hesselmann
Rolf Hesselmann
Clemens DecristoforoClemens Decristoforo
Clemens Decristoforo
Background: Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access to and availability of radiopharmaceuticals. Main body: This paper summarises major considerations for a suitable pharmaceutical regulatory framework to facilitate patient access to radiopharmaceuticals. These include the distinct characteristics of radiopharmaceuticals which require dedicated regulations, considering the impact of the variable complexity of radiopharmaceutical preparation, personnel requirements, manufacturing practices and quality assurance, regulatory authority interfaces, communication and training, as well as marketing authorisation procedures to ensure availability of radiopharmaceuticals. Finally, domestic and regional supply to ensure patient access via alternative regulatory pathways, including in-house production of radiopharmaceuticals, is described, and an outlook on regulatory challenges faced by new developments, such as the use of alpha emitters, is provided. Conclusions: All these considerations are an outcome of a dedicated Technical Meeting organised by the IAEA in 2023 and represent the views and opinions of experts in the field, not those of any regulatory authorities.

1 May 2018 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
JAJAN ANDERSSON
JAN ANDERSSON
BTB. Thomas
B. Thomas
SSSvetlana V. Selivanova
Svetlana V. Selivanova
EBE. Berthelette
E. Berthelette
JWJ.S. Wilson
J.S. Wilson
KGKatherine Gagnon
Katherine Gagnon

1 April 2016 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
JAJAN ANDERSSON
JAN ANDERSSON
JWJ.S. Wilson
J.S. Wilson
JRJ.A. Romaniuk
J.A. Romaniuk
AMA.J.B. McEwan
A.J.B. McEwan
DAD.N. Abrams
D.N. Abrams
KGKatherine Gagnon
Katherine Gagnon

20 July 2016 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JJJ. Johansson
J. Johansson
LOLars Olson
Lars Olson
JAJAN ANDERSSON
JAN ANDERSSON
GJG. Johansson
G. Johansson
BWB. Winblad
B. Winblad
Content List – Read more articles from the symposium: Amyloid ‐ a multifaceted player in human health and disease.